1. Ghimire P, Wu GY, Zhu L. Primary gastrointestinallymphoma. World J Gastroenterol. Feb 142011;17(6):697-707. doi:10.3748/wjg.v17.i6.697 [DOI:10.3748/wjg.v17.i6.697]

2. Wang YG, Zhao LY, Liu CQ, et al. Clinicalcharacteristics and prognostic factors of primarygastric lymphoma: A retrospective study with 165cases. Medicine (Baltimore). Aug 2016;95(31):e4250.doi:10.1097/md.0000000000004250 [DOI:10.1097/MD.0000000000004250]

3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organizationclassification of lymphoid neoplasms. Blood.May 19 2016;127(20):2375-90. doi:10.1182/blood-2016-01-643569 [DOI:10.1182/blood-2016-01-643569]

4. Violeta Filip P, Cuciureanu D, Sorina DiaconuL, Maria Vladareanu A, Silvia Pop C. MALTlymphoma: epidemiology, clinical diagnosis andtreatment. J Med Life. Jul-Sep 2018;11(3):187-193.doi:10.25122/jml-2018-0035 [DOI:10.25122/jml-2018-0035]

5. Mulalic E, Delibegovic S. An Aggressive Form ofMALT Lymphoma of the Stomach with PancreasInfiltration. Med Arch. Jun 2016;70(3):235-7.doi:10.5455/medarh.2016.70.235-237 [DOI:10.5455/medarh.2016.70.235-237]

6. Kuo SH, Yeh KH, Wu MS, et al. Helicobacterpylori eradication therapy is effective in thetreatment of early-stage H pylori-positive gastricdiffuse large B-cell lymphomas. Blood. May 242012;119(21):4838-44; quiz 5057. doi:10.1182/blood-2012-01-404194 [DOI:10.1182/blood-2012-01-404194]

7. Huang WT, Kuo SH, Kuo YC, Lin CW. miR-155-regulated mTOR and Toll-like receptor 5 in gastricdiffuse large B-cell lymphoma. Cancer Med. Feb2022;11(3):555-570. doi:10.1002/cam4.4466 [DOI:10.1002/cam4.4466]

8. Takahara T, Nakamura S, Tsuzuki T, Satou A. TheImmunology of DLBCL. Cancers (Basel). Jan 292023;15(3)doi:10.3390/cancers15030835 [DOI:10.3390/cancers15030835]

9. de Jong D, Enblad G. Inflammatory cells and immunemicroenvironment in malignant lymphoma. J InternMed. Dec 2008;264(6):528-36. doi:10.1111/j.1365-2796.2008.02032.x [DOI:10.1111/j.1365-2796.2008.02032.x]

10. Lam LT, Wright G, Davis RE, et al. Cooperativesignaling through the signal transducer and activatorof transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-celllymphoma. Blood. Apr 1 2008;111(7):3701-13.doi:10.1182/blood-2007-09-111948 [DOI:10.1182/blood-2007-09-111948]

11. Hirano T, Yasukawa K, Harada H, et al.Complementary DNA for a novel humaninterleukin (BSF-2) that induces B lymphocytesto produce immunoglobulin. Nature. Nov 6-121986;324(6092):73-6. doi:10.1038/324073a0 [DOI:10.1038/324073a0]

12. Rousset F, Garcia E, Defrance T, et al. Interleukin is a potent growth and differentiation factor foractivated human B lymphocytes. Proc Natl AcadSci U S A. Mar 1 1992;89(5):1890-3. doi:10.1073/pnas.89.5.1890 [DOI:10.1073/pnas.89.5.1890]

13. Voorzanger N, Touitou R, Garcia E, et al. Interleukin)IL(-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperativegrowth factors. Cancer Res. Dec 1 1996;56(23):5499-505.

14. Blay JY, Burdin N, Rousset F, et al. Seruminterleukin-10 in non-Hodgkin's lymphoma: aprognostic factor. Blood. Oct 1 1993;82(7):2169-74. [DOI:10.1182/blood.V82.7.2169.bloodjournal8272169]

15. Gupta M, Han JJ, Stenson M, et al. Elevated serumIL-10 levels in diffuse large B-cell lymphoma: amechanism of aberrant JAK2 activation. Blood.Mar 22 2012;119(12):2844-53. doi:10.1182/blood-2011-10-388538 [DOI:10.1182/blood-2011-10-388538]

16. Giachelia M, Voso MT, Tisi MC, et al. Interleukin-6plasma levels are modulated by a polymorphism inthe NF-κB1 gene and are associated with outcomefollowing rituximab-combined chemotherapy indiffuse large B-cell non-Hodgkin lymphoma. LeukLymphoma. Mar 2012;53(3):411-6. doi:10.3109/10428194.2011.621566 [DOI:10.3109/10428194.2011.621566]

17. Budakoti M, Panwar AS, Molpa D, et al. Micro-RNA: The darkhorse of cancer. Cell Signal. Jul2021;83:109995. doi:10.1016/j.cellsig.2021.109995 [DOI:10.1016/j.cellsig.2021.109995]

18. Jabłońska E, Białopiotrowicz E, Szydłowski M, Prochorec-Sobieszek M, Juszczyński P, Szumera-Ciećkiewicz A. DEPTOR is a microRNA-155target regulating migration and cytokine productionin diffuse large B-cell lymphoma cells. ExpHematol. Aug 2020;88:56-67.e2. doi:10.1016/j.exphem.2020.07.005 [DOI:10.1016/j.exphem.2020.07.005]

19. Fangazio M, Ladewig E, Gomez K, et al. Geneticmechanisms of HLA-I loss and immune escape indiffuse large B cell lymphoma. Proc Natl Acad Sci U SA. Jun 1 2021;118(22)doi:10.1073/pnas.2104504118 [DOI:10.1073/pnas.2104504118]

20. Raskov H, Orhan A, Christensen JP, Gögenur I.Cytotoxic CD8)+(T cells in cancer and cancerimmunotherapy. Br J Cancer. Jan 2021;124(2):359-367. doi:10.1038/s41416-020-01048-4 [DOI:10.1038/s41416-020-01048-4]

21. Reimann M, Schrezenmeier J, Richter-Pechanska P, et al. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-celllymphomas. Blood. May 20 2021;137(20):2785-2799. doi:10.1182/blood.2020005244 [DOI:10.1182/blood.2020005244]

22. Xu W, Berning P, Lenz G. Targeting B-cellreceptor and PI3K signaling in diffuse large B-celllymphoma. Blood. Sep 30 2021;138(13):1110-1119.doi:10.1182/blood.2020006784 [DOI:10.1182/blood.2020006784]

23. Davis RE, Ngo VN, Lenz G, et al. Chronic activeB-cell-receptor signalling in diffuse large B-celllymphoma. Nature. Jan 7 2010;463(7277):88-92.doi:10.1038/nature08638 [DOI:10.1038/nature08638]